Llama Biotech makes €600M deal with AbbVie for Immuno-Oncology

21/04/2016 - 2 minutes

Ghent based argenx has just partnered up with the French AbbVie to develop a novel antibody derived from llamas – in its biggest deal ever!

argenx_abbvie_immunooncology_cancer_deal_biotech_agx115Having been better known for their work into autoimmune diseases, argenx has now also broken into the Immuno-Oncology field – big time.

Previous collaborators have included Denmark’s Leo Pharma for inflammatory skin diseases, although this collaboration was not even a 1/6th of the value of the new deal with AbbVie.

AbbVie is well known for its clout in the Oncology field, and has now stepped in to work alongside argenx to develop and commercialize the ARGX-115 antibody, derived from our favourite animals here at Labiotech – llamas.

This is a similar approach to which Ablynx (another Belgian biotech) approaches antibody engineering, well known for its Camelidae mAbs.

ARGX-115 is argenx’s preclinical-stage human antibody targeting the novel cancer target GARP,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member